Kenya PPB: Pharmacy and Poisons Board Explained
Understand the Pharmacy and Poisons Board’s role in Kenya, the product categories it lists and how to organise a focused applicant-readiness review.

On this page · 10 sections
- 1What Kenya PPB is and what it regulates
- 2Kenya’s regulatory framework and PPB’s organisational responsibilities
- 3Products PPB lists: a Kenya-specific scope map
- 4PPB, product registration and licences: terms compared
- 5Medical-device and IVD applications: PPB’s stated sequence
- 6Device application pathways and the eligibility references
- 7An internal readiness lifecycle before and after submission
- 8Three worked cases: routing, prerequisites and record conflicts
- 9PPB safety reporting and post-market information
- 10A final readiness checklist and preventable failure modes
How does PPB (Kenya) apply to your shop floor?
Pick your industry and scale — Ask V5 rewrites the definition in your context, gives a worked example, and shows what V5 does on day one.
01What Kenya PPB is and what it regulates
Kenya PPB is the Pharmacy and Poisons Board, Kenya’s drug regulatory authority established under the Pharmacy and Poisons Act, Chapter 244, according to PPB’s description of its statutory basis. The name identifies the organisation—not an application, a licence or a decision about an individual product.
In the second paragraph of its About Us description, PPB states that it regulates pharmacy practice and the manufacture and trade in drugs and poisons. Its stated remit therefore concerns both professional practice and activities involving products; describing PPB only as a product-registration service would miss part of that remit.
The Board’s stated regulatory aims include achieving the highest standards of safety, efficacy and quality for drugs, chemical substances and medical devices. This is a statement of the Board’s aims, not a product-specific finding that every item within those categories has achieved those standards.
For practical recordkeeping, use “PPB” as the authority name and describe the relevant application, licence or decision separately. A note saying only “PPB status” leaves the subject unclear: the organisation’s identity does not describe what has happened to a particular submission. In multi-country reference records, keep the Kenya authority entry separate from entries such as South Africa’s SAHPRA. These are internal clarity practices, not additional PPB submission requirements.
02Kenya’s regulatory framework and PPB’s organisational responsibilities
Legal authority and official instructions
PPB’s Our Mandate statement identifies the Board as the Drug Regulatory Authority established under the Pharmacy and Poisons Act, Chapter 244 of the Laws of Kenya. For statutory scope, check the current Act. The organisational descriptions below explain how PPB presents its work; they are not a substitute for the legislation.
Keep three layers separate when planning an application: binding legislation, PPB’s official procedural instructions for the relevant service, and optional company readiness controls. A directorate’s name alone should not be used to infer an application requirement or approval power.
The four directorates
PPB’s Organisation of the Board section lists four directorates: Medical Products and Health Technologies, Pharmacy Practice, Laboratory Services and Corporate Services.
- Medical Products and Health Technologies: under the heading Medical Products and Technologies, PPB attributes registration of medical products and health technologies; inspections and enforcement of good practices for manufacturing and distribution; post-market surveillance; clinical trials; and vigilance to this function.
- Pharmacy Practice: PPB’s function description addresses regulation of pharmacy training, practice and continuing professional development to maintain competence and fitness to practice.
- Laboratory Services: PPB’s Laboratory Services description covers compliance testing of medical products, technologies and their ingredients using authorised methods, plus investigative testing of suspicious, substandard, falsified, illegal or counterfeit substances or products.
- Corporate Services: PPB's Corporate Services description says it is concerned with the financial, human resource and administrative management functions of the Board and consolidates the support services needed for its operational work. The same page lists departments and units under the office of the chief executive officer, including Trade Affairs, Licit Control, Regional Offices, Corporate Secretary/Legal Services, Supply Chain Management, and Planning QMS and Research, and notes that Internal Audit and Risk Management reports to the Board Directors.
Using the structure internally
Treat this structure as a routing aid, not an applicant testing checklist. For manufacturing terminology, the cGMP glossary provides background rather than Kenya-specific application instructions.
The readiness workflow and record model later in this article are suggested internal controls, not legal provisions or PPB submission specifications. Use them to assign company owners, preserve the applicable instruction and document unresolved questions. Keep each internal task distinguishable from the official instruction it supports, so reviewers can tell company procedure from a regulator’s direction.
03Products PPB lists: a Kenya-specific scope map
PPB’s homepage lists seven entries under Products regulated by PPB, reproduced below. This is the Board’s published product-scope list; use it to identify the category whose instructions need attention, rather than as a product-specific application checklist.
The routing questions are suggested internal planning prompts, not PPB requirements. Each asks which instructions apply without assuming a registration condition or assigning a product to a category solely from its commercial description.
| Jurisdiction | PPB product entry | Official reference | Applicant’s routing question |
|---|---|---|---|
| Kenya | Medicines | PPB homepage product list | Which PPB medicines instructions apply to this product? |
| Kenya | Vaccines and Biologicals | PPB homepage product list | Which PPB instructions address this vaccine or biological? |
| Kenya | Blood & Blood Products | PPB homepage product list | Which category-specific PPB instructions apply to this product? |
| Kenya | Medical Devices and IVDs | PPB homepage product list | Which device or IVD instructions apply? See “Medical-device and IVD applications: PPB’s stated sequence” below. |
| Kenya | Cosmetics | PPB homepage product list | Which PPB cosmetics instructions govern the proposed action? |
| Kenya | Food Supplements | PPB homepage product list | Which PPB food-supplement instructions apply to this product? |
| Kenya | Herbal and Complementary Medicines | PPB homepage product list | Which PPB instructions apply within this category? |
Cosmetics
Cosmetics appear explicitly in PPB’s published scope. For application planning, determine the applicable action from the relevant PPB cosmetics instructions rather than borrowing the device procedure. The category label is a starting point for that inquiry, not a substitute for those instructions.
Food supplements
Food Supplements also appear explicitly. Apply the same category-specific boundary: identify the relevant PPB instructions before deciding what action to take. Keep the internal routing decision tied to the product and the intended action, with unresolved applicability questions clearly marked for follow-up.
Keep general manufacturing-quality topics, such as cGMP, separate from this category-routing exercise. They can inform internal readiness discussions, but should not be used to infer a Kenya-specific application step from a product-category name.
05Medical-device and IVD applications: PPB’s stated sequence
PPB’s Medical Devices Evaluation and Registration Procedure gives applicants a sequence for marketing authorisation (MA). The steps below describe that published guidance; the internal tracking recommendations that follow are recordkeeping practice, not additional PPB application requirements.
Follow the application steps
- Apply for GMP inspection before submitting the MA application. In section 1, MA application, PPB says applicants must apply for GMP inspection before submitting an application for MA and refers them to the GMP inspection and Compliance procedure. Preserve the action exactly: apply for GMP inspection. Do not rewrite this step as obtaining a satisfactory inspection outcome. For background terminology, see current good manufacturing practice (cGMP); PPB’s named procedure remains the reference for this application step.
- Meet the guideline’s minimum requirements. For medical devices or in vitro diagnostics (IVDs), section 1 of the procedure directs applicants to meet the minimum requirements described in the guideline. Use those requirements as the application reference. An internal readiness checklist may help organise work, but it is not a substitute for the guideline or a separate definition of what PPB requires.
- Complete the online form. Section 1 directs applicants to prims.pharmacyboardkenya.org and to fill in the application form according to the requirements in the Guidelines on Medical Devices evaluation and registration. Keep that named guideline alongside the form when preparing the application, rather than treating form completion as an independent exercise.
- Follow the invoice and payment sequence. Section 1 states that completing the form generates an invoice and instructs applicants to make the payments to complete the application. This is the stated administrative sequence: form completion, invoice generation, then payment to complete the application.
- Apply for GMP inspectionBefore submitting the MA application, via the GMP inspection and Compliance procedure.
- Meet Minimum RequirementsAs described in the guideline for medical devices or IVDs.
- Complete the Online FormOn prims.pharmacyboardkenya.org, per the Guidelines on Medical Devices evaluation and registration.
- Invoice GeneratedOn completion of the form.
- Make the paymentTo complete the application.
Keep milestone records distinct
As an internal recordkeeping practice, use separate tracker entries for the events below. Each entry should describe its own event, rather than allowing one administrative milestone to stand for another.
| Tracker entry | Recommended recording boundary |
|---|---|
| Inspection request | Record the application for inspection as a request, not an inspection result. |
| Inspection outcome | Record the outcome separately, using the relevant outcome record. |
| Payment record | Record the payment event without relabelling it as a regulatory decision. |
| Regulatory decision | Record the decision separately from inspection and payment milestones. |
Avoid a single “complete” status that conceals which event occurred. A reviewer should be able to distinguish preparation, inspection-related records, payment and the decision record without inferring one from another.
06Device application pathways and the eligibility references
PPB’s medical-device procedure, section 1 groups application submission into three pathways. The grouping matters: full assessment and Reliance sit within Fasttrack, rather than appearing as separate pathways alongside it.
- First in first out (FIFO)
- Fasttrack (full assessment and Reliance)
- expedited pathway (emergency use authorization)
Where to assess eligibility
For eligibility, the same section directs applicants to these three named guidance documents:
- Reliance guidelines on regulatory decision making in Kenya
- Guidelines for fast track review of applications for Health products
- Guidelines on submission of documentation for emergency use and compassionate use authorization of health products
Use those references to investigate eligibility, rather than treating a pathway name as a qualifying condition. Keep the proposed route distinct from the conclusion reached after reviewing the applicable guidance.
A compact internal pathway assessment
The following is a suggested internal decision aid, not a PPB-required form. Assign a responsible reviewer and retain the reasoning behind the proposal.
| Record | Useful entry |
|---|---|
| Proposed pathway | Use PPB’s grouping; identify the Fasttrack option where relevant. |
| Applicable guidance reference | Record the exact document title used for the assessment. |
| Unresolved eligibility question | State the specific point needing clarification. |
| Responsible reviewer | Name the person accountable for resolving that question. |
| Conclusion | Record the reasoned proposal, or leave eligibility unresolved. |
For cross-market planning, keep any 510(k) pathway assessment separate from this Kenya-specific decision. Do not use another market’s route name as the rationale for selecting a PPB pathway. Likewise, avoid converting “Fasttrack” or “expedited” into an assumed review duration or approval outcome. The internal assessment should document a proposal and its basis, not substitute for a regulatory decision.
07An internal readiness lifecycle before and after submission
Use the following seven stages as a suggested company workflow, separate from PPB’s application and decision sequence. They organise internal work around the relevant service; they are not mandatory PPB stages or an assurance of acceptance. For devices, retain the milestone distinctions covered above rather than treating internal readiness as a regulatory milestone.
Each output answers a different operational question: what is the product, where should the work go, which instructions apply, who owns the evidence, what conflicts remain, who authorised the handover, and what happens next? These are suggested working records, not a mandatory dossier list. Combine them where useful, but keep ownership and unresolved questions visible.
Suggested internal workflow — seven stages for applicant coordination
- Describe the product. The product lead prepares a product description identifying the item and intended use, with uncertainties marked for regulatory review rather than silently resolved.
- Identify the relevant PPB service. The regulatory lead creates a service-routing note explaining the proposed destination and any routing question that needs clarification before handover.
- Read applicable instructions. The regulatory lead records an instruction reference: document title, location, applicable section and review date. Link resulting tasks to that reference.
- Assign evidence owners. The coordinator prepares an ownership list naming a contributor and reviewer for each task, then confirms that contributors understand the requested output.
- Reconcile working records. Contributors and reviewers produce a discrepancy review comparing product identifiers, versions and statements. Where change history matters, use an audit trail review workflow to investigate differences.
- Authorise the team’s handover. Authorised internal reviewers approve a handover record identifying the agreed version, recipient and unresolved issues. This decision concerns the team’s work, not PPB’s decision.
- Track feedback and follow-up. The submission coordinator maintains an open-action log with each question, owner, response status and next action, returning changed records to the relevant reviewer.
- Describe the ProductRecord its identity and the proposed product category.
- Map the serviceIdentify the PPB service relevant to the intended action.
- Read applicable instructionsRecord the official reference and unresolved questions.
- Assign evidence ownersGive working records and open questions named owners.
- Reconcile working recordsResolve conflicting identifiers, versions and status descriptions.
- Authorise Team HandoverAn authorised person reviews readiness and outstanding actions.
- Track feedbackRecord correspondence, decisions and assigned follow-up actions.
Records that keep the application traceable
| Suggested entity | Internal purpose |
|---|---|
| Product record | Identify the product and its proposed category. |
| Instruction reference | Identify the applicable instructions and the version used. |
| Application record | Link the product, instructions, supporting working records and unresolved actions. |
| Evidence item | Locate a supporting controlled document or working record and its version. |
| Review action | Record an open question, responsible owner and review outcome. |
If values disagree, preserve both conflicting records rather than overwriting the history. Identify the affected field and versions, assign an owner and determine the appropriate correction route. Obtain authorised review, then retain a resolution record linking the discrepancy, decision and resulting records. An audit trail review workflow can help structure that internal check.
Where the uncertainty concerns an existing PPB application, consult the relevant PPB instructions or enquiry channel before acting. Do not assume that changing an internal record changes a submitted application or that submitted information can be edited.
08Three worked cases: routing, prerequisites and record conflicts
These hypothetical cases apply the distinctions explained above to two routing decisions; they are not additional PPB requirements.
Case one: inspection application not yet made
Assumption: A company is preparing a medical-device marketing authorisation (MA) application but has not yet applied for GMP inspection.
Decision: Organise the inspection application before submitting the MA application; do not treat the two steps as interchangeable.
Reasoning: Section 1 of PPB's medical-device procedure sets the order; the milestone distinction above explains why the application is not an outcome.
Next action: Assign the responsible applicant to consult the referenced GMP inspection and Compliance procedure and make the inspection application before MA submission.
Case two: proposed cosmetic, unresolved instructions
Assumption: A manufacturer describes its proposed product as a cosmetic but has not resolved which product-specific instructions apply.
Decision: Clarify the category question rather than adopting the device checklist.
Reasoning: PPB’s Products regulated by PPB list includes Cosmetics. That category listing alone does not resolve this product’s classification or identify its application instructions. Internally, prepare a concise product description covering its intended use, presentation and proposed claims, then identify precisely what remains uncertain.
Next action: Send PPB a focused enquiry with that description, asking which category and product-specific instructions to consult; retain the response with the routing decision.
09PPB safety reporting and post-market information
PPB’s homepage lists Market Surveillance and Control and Vigilance among its regulatory functions. These are PPB’s published function labels, rather than product-specific reporting instructions.
For public reporting, the homepage provides “Report Adverse Events & Poor Quality Medicines” and “Submit Complaints” entries. Its “Safety Communication and Recalls” navigation also includes “Recalls”, “Safety Communication” and “Rapid Alerts”. Manufacturers can use these named entries to locate reporting routes and public safety information.
As an internal practice, assign an owner to review relevant public communications and route concerns to appropriate quality, regulatory or safety personnel. Connect that review with your post-market surveillance, adverse-event reporting and customer complaint processes. This is a suggested organisational control, not a statement of PPB reporting obligations or deadlines.
10A final readiness checklist and preventable failure modes
Use this proposed internal checklist at the handover meeting. It is not an official PPB checklist or a complete submission specification. Assign an actual person to each role and record the result against the working record’s version.
| Review item | Responsible person | Recorded result |
|---|---|---|
| Product and service identification | Regulatory lead | Selected category and service, or routing question |
| Applicable instructions | Application coordinator | Instruction reference and version used |
| Unresolved pathway questions | Regulatory reviewer | Eligibility conclusion or open question |
| Prerequisites | Activity owner | Status and supporting record reference |
| Record reconciliation | Document controller | Agreed version and discrepancy disposition |
| Action ownership | Project lead | Named owner and next action for each issue |
| Authorised handover | Designated approver | Permitted next action and authorised recipient |
Test the review against four preventable internal failures—not assumed PPB rejection reasons:
Close with a dated handover decision: what is ready, what remains unresolved, and who is authorised to act next. State whether the next action is clarification, correction or submission. As distinguished earlier, internal readiness is not the regulator’s decision.
Does PPB list cosmetics and food supplements, or only medicines?
PPB’s “Products regulated by PPB” list includes Cosmetics and Food Supplements alongside Medical Devices and IVDs and other categories. If your team is preparing a cosmetic product, use that listing as the starting point for the scope check discussed above—not as a substitute for product-specific instructions. A useful internal next step is to document the proposed category, the intended service and the question needing clarification. Avoid copying the device procedure into a cosmetics checklist merely because both categories appear on the same website.
A colleague says “get the PPB licence.” What should I clarify?
Ask which service they mean. PPB’s “Apply For” menu separately names Marketing Authorisation / Product Registration, Premises License and Practice License. For an internal request, record the exact service name rather than leaving “PPB licence” as the task description. As the terms comparison above explains, a service label should not be stretched into a conclusion about its legal effect. Have the requester identify the product, premises or person concerned and the intended next action; then assign the clarification to the appropriate internal reviewer before preparing records.
Can commercial urgency justify choosing Fasttrack for a device?
Do not use a launch date alone as the internal justification. For eligibility, PPB’s device procedure, paragraph 1, directs applicants to named reliance, fast-track and emergency-use/compassionate-use guidance. As covered in the pathways section, those references are the place to resolve the eligibility question. Ask the regulatory reviewer to record the relevant guidance, the basis for the proposed choice and any unanswered point. If the review remains inconclusive, hand over a defined clarification question rather than recording the preferred pathway as an established entitlement in the project plan.
The device application form is complete. Is the application complete?
Do not equate those two milestones. PPB’s device procedure, paragraph 1, states that an invoice will be generated upon completion of the form and instructs applicants to make the payments to complete the application. For internal tracking, record form completion and the payment step separately, with the relevant records attached or referenced. This follows the sequence discussed above without assuming a fee amount or processing time. Before handover, have the coordinator reconcile the recorded status with the supporting records rather than relying on a verbal update.
Where should a team start with a safety concern or complaint?
PPB’s home-page reporting links include “Report Adverse Events & Poor Quality Medicines” and “Submit Complaints.” If a concern arises during application preparation, assign it to the appropriate internal safety or quality owner rather than treating it merely as an application-record correction. As discussed in the safety section, use the relevant official reporting route and its instructions. Keep the application team informed of any associated record changes through a separate, documented handover. These links alone do not establish a reporting deadline or the contents of a report.
Frequently asked questions
Q.What should a company include in an enquiry when its PPB product category is unclear?+
As an enquiry-preparation practice, provide the product name, composition or materials, presentation, intended purpose, proposed users and exact label claims. Explain which category is uncertain and ask a focused classification question rather than asserting an answer. Attach clearly identified versions of relevant labels or specifications. Distinguish the label claim from internal release limits, and describe any critical quality attribute relevant to the uncertainty. This is a suggested enquiry structure, not a PPB submission checklist.
Q.How can a business organise its questions when more than one PPB service appears relevant?+
Use an internal question matrix: one row per issue, with the product or site concerned, the clarification sought, the responsible colleague and any dependency on another answer. Separate questions about the product from questions about premises, manufacturing activities or professional practice without assuming that one response resolves all of them. Put consequential uncertainties in a quality risk register. A shared coordination board can help colleagues track dependencies; it should not turn tentative interpretations into agreed regulatory positions.
Q.Does PPB only regulate products, or also pharmacy professionals?+
Both. Alongside product registration, PPB's organisation description places regulation of pharmacy training, practice and continuing professional development with its Pharmacy Practice directorate, aimed at maintaining competence and fitness to practise. Its Laboratory Services directorate separately covers compliance testing of medical products, technologies and their ingredients, and investigative testing of suspicious, substandard or falsified products. A manufacturer preparing a product application will mainly deal with the Medical Products and Health Technologies function, but pharmacy premises and practice licences are separate services on PPB's site.
Q.How should an applicant assess an urgent launch request without assuming emergency-use eligibility?+
PPB’s medical-device procedure, paragraph 1, identifies an expedited pathway for emergency use authorization and directs applicants to eligibility guidance, including the Guidelines on submission of documentation for emergency use and compassionate use authorization of health products. As an internal assessment practice, document the reason for urgency and identify which eligibility questions need resolution. Keep the requested launch date on the production schedule board as a planning assumption, not evidence that the product qualifies.
Q.How can a manufacturer route a concern about a PPB safety communication to the right internal people?+
For internal triage, preserve the communication’s title, date, link and affected product identifiers, then describe the concern precisely. Route interpretation questions to regulatory affairs, potential patient or user harm to the designated safety lead, and possible product-quality issues to quality assurance. Include distribution colleagues where stock location matters. Use the organisation’s recall-readiness process to coordinate any resulting assessment, without pre-labelling the concern as a recall. Assign an owner to document the decision and follow-up actions.
Q.What should a regulatory handover include when responsibility changes before a PPB decision?+
As a continuity practice, hand over the application identifier, product and scope, submitted document versions, correspondence, unresolved questions and next actions. Distinguish the last submission from later internal drafts, and identify who can approve responses. Include outstanding commitments with their source and responsible owner rather than relying on memory. Adapt a handover report to the regulatory workstream, using contemporaneous recording for subsequent updates. The incoming owner should acknowledge the open items and confirm access through approved account arrangements.
Primary sources
Want to see how PPB (Kenya) could fit into your own records and workflows? Explore the related V5 pages or talk to our team about what applies to your operation.
